Neuropathic Pain News and Research

RSS

Neuropathic pain is a type of pain that is caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population.

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

University of Michigan to develop novel therapy for neuropathic pain

Researchers from the University of Michigan Department of Neurology have received a $1.8 million dollar grant to develop a novel therapy for neuropathic pain, a difficult to treat condition in which patients experience pain because of damage to nerve without obvious tissue injury.

10 Nov 2009

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Raptor Pharmaceutical Corp., today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

5 Nov 2009

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Thanks to a two year, $974,024 NIH-funded ARRA (American Recovery and Reinvestment Act) grant, Saint Louis University and Southern Illinois University Edwardsville researchers are working to find better ways to manage chronic pain by treating neuroinflammation.

4 Nov 2009

NIH awards $2 million grant for sickle cell disease research

Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it.

2 Nov 2009

Folate-enriched prescription medical food lowers medical costs of patients with peripheral neuropathy

Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress.

28 Oct 2009

HealthCore study shows Metanx tablets reduces health plan costs

27 Oct 2009

Pregabalin reduces abdominal pain and improves sleep in women with adhesions

Pregabalin, FDA-approved for neuropathic pain (pain caused by shingles and peripheral neuropathy), effectively reduced abdominal pain and improved sleep in women with adhesions, according to a Henry Ford study.

27 Oct 2009

Lack of optimal pain care delivery system costs more than $100 billion each year

A new Pain Medicine Position Paper published by leaders of the American Academy of Pain Medicine (AAPM), reveals businesses lose $61 billion annually due to ineffective pain care and the lack of optimal pain care delivery.

27 Oct 2009

NIH grant for Lpath to advance clinical development of its antibody therapeutics

The National Cancer Institute's Small Business Innovation Research (SBIR) Program has awarded Lpath (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, two Phase 1 grants totaling $0.3 million. This follows a series of other SBIR grants awarded to Lpath totaling $6.9 million, including a $3.0 million Phase 2 bridge grant from the NCI awarded this past June.

21 Oct 2009

Positive results from KAI Pharmaceuticals' pain therapeutic program

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced positive preclinical results from its program targeting the gamma protein kinase C (PKC) pathway for the development of novel therapies for pain.

20 Oct 2009

Brain researcher finds how the epilepsy and pain drug works

A Duke University Medical Center researcher who spent years looking for the signals that prompt the brain to form new connections between neurons has found one that may explain precisely how a well-known drug for epilepsy and pain actually works.

14 Oct 2009

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia

GlaxoSmithKline and XenoPort, Inc. today announced top-line results from a Phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher.

5 Oct 2009

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

GVK Biosciences (GVK BIO), Asia’s leading integrated research services provider and Quantitative Solutions (QS), a modeling and simulation (M&S) consultancy to the pharmaceutical and biotech industry, announced a strategic partnership to develop and market clinical trial outcome databases.

5 Oct 2009

New drug combination releives neuropathic pain and improves sleep

People who suffer from debilitating neuropathic pain may get more relief and sleep better by combining two commonly-prescribed drugs.

1 Oct 2009

Pfizer to continue its Aricept agreement with Eisai

Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption. Under this redefined alliance, which resolves a previously disclosed dispute, Pfizer and Eisai will continue to co-promote Aricept in the U.S., Japan and key markets in Europe, and Pfizer will continue to have an exclusive license to sell Aricept in the other countries where it has rights.

25 Sep 2009

Aegera Therapeutics raises $7 Million for additional working capital

Aegera Therapeutics, a clinical stage biotechnology company focussed on developing targeted therapeutics for oncology and pain, announced today the full drawdown of a $7 Million debt facility provided by Investissement Quebec.

24 Sep 2009

Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced

GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia (PHN) in adults.

17 Sep 2009

Six-month period financial results released by Cannasat Therapeutics

Cannasat Therapeutics Inc., a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the six months ended June 30, 2009. Unless specified otherwise, all amounts are in Canadian dollars.

1 Sep 2009

Neuropathic Pain News and Research

Further Reading

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

University of Michigan to develop novel therapy for neuropathic pain

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Researchers to find better ways to manage chronic pain by treating neuroinflammation

NIH awards $2 million grant for sickle cell disease research

Folate-enriched prescription medical food lowers medical costs of patients with peripheral neuropathy

HealthCore study shows Metanx tablets reduces health plan costs

Pregabalin reduces abdominal pain and improves sleep in women with adhesions

Lack of optimal pain care delivery system costs more than $100 billion each year

NIH grant for Lpath to advance clinical development of its antibody therapeutics

Positive results from KAI Pharmaceuticals' pain therapeutic program

Brain researcher finds how the epilepsy and pain drug works

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

New drug combination releives neuropathic pain and improves sleep

Pfizer to continue its Aricept agreement with Eisai

Aegera Therapeutics raises $7 Million for additional working capital

Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced

Six-month period financial results released by Cannasat Therapeutics

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News